M. Schwemmlein

Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems.

R. Kontermann, O. Heidenreich, D. Müller, 2010, Journal of controlled release : official journal of the Controlled Release Society.

A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells

P. Lang, G. Fey, M. Peipp, 2008, Journal of immunotherapy.

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability

T. Bijma, G. Fey, G. Huls, 2009, Leukemia.

A CD33‐specific single‐chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells

D. Saul, B. Emmerich, G. Fey, 2006, British journal of haematology.

Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

A. Mackensen, H. Lanig, M. Aigner, 2010, Journal of immunotherapy.

A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells

D. Saul, P. Lang, B. Emmerich, 2007, Leukemia.

A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells

D. Nettelbeck, S. Ferrone, G. Fey, 2008, Melanoma research.